News in Brief
Health - Jan 11
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Pharmacology - Jan 11
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
History - Jan 10
THURS 28 JAN.: MAKING ART MODERN? VIEWS FROM THE ITALIAN RENAISSANCE- Talk by Robert Brennan with a response by Wolf-Dietrich Löhr
THURS 28 JAN.: MAKING ART MODERN? VIEWS FROM THE ITALIAN RENAISSANCE- Talk by Robert Brennan with a response by Wolf-Dietrich Löhr
Environment - Jan 7
More Root Carbon in Extensive Cultivation Systems - the Greenhouse Gas Inventory Is Optimised
More Root Carbon in Extensive Cultivation Systems - the Greenhouse Gas Inventory Is Optimised
Economics - Jan 7
Keep it simple: Exploring the precarious world of economic forecasting with Prof Michael Gasiorek
Keep it simple: Exploring the precarious world of economic forecasting with Prof Michael Gasiorek
science wire
« BACK
Health - Pharmacology - 20.08.2020
Health - Pharmacology - 20.08.2020
Pharmacology - Mathematics - 20.08.2020
Health - Pharmacology - 19.08.2020
Pharmacology - Social Sciences - 18.08.2020
Health - Pharmacology - 17.08.2020
Pharmacology - Health - 17.08.2020
Health - Pharmacology - 17.08.2020
Pharmacology - Health - 13.08.2020
Pharmacology - Health - 13.08.2020
Pharmacology - Health - 13.08.2020
Health - Pharmacology - 13.08.2020
Computer Science - Pharmacology - 13.08.2020
Health - Pharmacology - 12.08.2020
Pharmacology - Health - 12.08.2020
Pharmacology - Health - 11.08.2020
Pharmacology - Health - 11.08.2020
Health - Pharmacology - 11.08.2020
Pharmacology - Health - 10.08.2020
Pharmacology - Health - 07.08.2020
Pharmacology - Health - 07.08.2020
Health - Pharmacology - 07.08.2020
Health - Pharmacology - 06.08.2020
Environment - Pharmacology - 06.08.2020
Pharmacology - Health - 06.08.2020
Health - Pharmacology - 06.08.2020
Health - Pharmacology - 05.08.2020
Pharmacology - Health - 05.08.2020
Pharmacology - Health - 05.08.2020
Pharmacology - Health - 04.08.2020
Health - Pharmacology - 03.08.2020
Pharmacology - Health - 03.08.2020
Health - Pharmacology - 03.08.2020
Health - Pharmacology - 30.07.2020
Health - Pharmacology - 30.07.2020
Pharmacology - Health - 30.07.2020
Health - Pharmacology - 29.07.2020
Pharmacology - Health - 29.07.2020
Pharmacology - 27.07.2020
Pharmacology - Health - 27.07.2020
Health - Pharmacology - 27.07.2020
Health - Pharmacology - 24.07.2020
Health - Pharmacology - 24.07.2020
Pharmacology - Health - 24.07.2020
Health - Pharmacology - 23.07.2020
Health - Pharmacology - 23.07.2020 
Finch Therapeutics unleashes the power of the gut
The company is developing treatments that restore gut bacteria in people struggling with a range of diseases.
Pharmacology - Health - 23.07.2020
Pharmacology - Economics / Business - 21.07.2020
Health - Pharmacology - 20.07.2020
Health - Pharmacology - 16.07.2020
Pharmacology
Results 201 - 250 of 2145.
One Life, Two Viruses: HIV and SARS-CoV-2
UC San Diego infectious disease researchers are striving to understand the complexities of living with HIV and acquiring COVID-19 E very day, she donned a mask and was vigilant about washing her hand
UC San Diego infectious disease researchers are striving to understand the complexities of living with HIV and acquiring COVID-19 E very day, she donned a mask and was vigilant about washing her hand
Analysis: How UCL clinicians invented a new way of treating breast cancer
As a large trial confirms the effectiveness of single-dose radiotherapy in treating breast cancer, Principle Investigator, Professor Jayant Vaidya (UCL Surgery & Interventional Science), describes how he and colleagues developed a new therapy which challenged convention.
As a large trial confirms the effectiveness of single-dose radiotherapy in treating breast cancer, Principle Investigator, Professor Jayant Vaidya (UCL Surgery & Interventional Science), describes how he and colleagues developed a new therapy which challenged convention.
Researchers extend recruitment to COVID-19 vaccine trial
Researchers at University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), North Bristol NHS Trust (NBT) and the University of Bristol have begun a new round of recruitment to a clinical trial of a vaccine pioneered in the UK which could protect against COVID-19.
Researchers at University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), North Bristol NHS Trust (NBT) and the University of Bristol have begun a new round of recruitment to a clinical trial of a vaccine pioneered in the UK which could protect against COVID-19.
YSM and Yale New Haven Hospital to test the new COVID-19 vaccine
Yale School of Medicine and Yale New Haven Hospital today announced the start of Phase 3 of the Pfizer vaccine trial at the hospital.
Yale School of Medicine and Yale New Haven Hospital today announced the start of Phase 3 of the Pfizer vaccine trial at the hospital.
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
Yale and Yale New Haven Hospital begin Phase 3 trial of COVID-19 vaccine
Yale School of Medicine and Yale New Haven Hospital today announced the start of Phase 3 of the Pfizer vaccine trial at the hospital.
Yale School of Medicine and Yale New Haven Hospital today announced the start of Phase 3 of the Pfizer vaccine trial at the hospital.
South Africa research team to establish ‘hub’ for discovery of new antibiotics
An international research collaboration, which includes the University of Bristol, has received funding to discover and accelerate the development of new antibiotics.
An international research collaboration, which includes the University of Bristol, has received funding to discover and accelerate the development of new antibiotics.
University of Minnesota opens clinical trial for new treatment of COVID-19
MyU : For Students, Faculty, and Staff COVID-19 Operational Updates A patient with COVID-19 and lung failure at the University of Minnesota is the first to be treated in the U.S. on a n
MyU : For Students, Faculty, and Staff COVID-19 Operational Updates A patient with COVID-19 and lung failure at the University of Minnesota is the first to be treated in the U.S. on a n
Opinion: Putin’s dangerous vaccine gamble
Prospective students Current students UCL in the media Services for media Tell us your story Professor Francois Balloux (UCL Genetics, Evolution & Environment) highlights the political sentiment
Prospective students Current students UCL in the media Services for media Tell us your story Professor Francois Balloux (UCL Genetics, Evolution & Environment) highlights the political sentiment
Over 55s needed for vaccine trial in Greater Glasgow and Clyde
People in good health and over the age of 55 years old are being asked to take part in a COVID-19 vaccine trial.
People in good health and over the age of 55 years old are being asked to take part in a COVID-19 vaccine trial.
Researchers to study the impact of Covid-19 in lower and middle-income countries
Glasgow researchers to study the impact of Covid-19 in lower and middle-income countries An international team of researchers, led by the University of Glasgow, has received an award to study the imp
Glasgow researchers to study the impact of Covid-19 in lower and middle-income countries An international team of researchers, led by the University of Glasgow, has received an award to study the imp
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
UK-India experts’ drive to stop antibiotic waste creating more ’superbugs’
Waste generated by India's drug manufacturing industry could be damaging environmental bacteria and creating ‘superbugs' that are resistant to antibiotics - prompting a UK-India scientific intervention. British and Indian researchers are joining forces to investigate the impact of waste release on microbial ecosystems - determining how much active antibiotic is released and which other potentially toxic chemicals are contained in the waste that may affect bacteria.
Waste generated by India's drug manufacturing industry could be damaging environmental bacteria and creating ‘superbugs' that are resistant to antibiotics - prompting a UK-India scientific intervention. British and Indian researchers are joining forces to investigate the impact of waste release on microbial ecosystems - determining how much active antibiotic is released and which other potentially toxic chemicals are contained in the waste that may affect bacteria.
UK-India experts’ drive to stop antibiotic waste creating more ’superbugs’
Waste generated by India's drug manufacturing industry could be damaging environmental bacteria and creating ‘superbugs' that are resistant to antibiotics - prompting a UK-India scientific intervention.
Waste generated by India's drug manufacturing industry could be damaging environmental bacteria and creating ‘superbugs' that are resistant to antibiotics - prompting a UK-India scientific intervention.
Qualcomm Institute-based Startup Receives Funding to Continue Development of Opioid Sensor
CARI Therapeutics, a member of UC San Diego's Qualcomm Institute Innovation Space , has received additional funding from the National Institute of Drug Abuse (NIDA) to refine their tiny implantable biosensor that could help combat the deadly and destructive opioid crisis in the United States.
CARI Therapeutics, a member of UC San Diego's Qualcomm Institute Innovation Space , has received additional funding from the National Institute of Drug Abuse (NIDA) to refine their tiny implantable biosensor that could help combat the deadly and destructive opioid crisis in the United States.
India-UK team tackles Antimicrobial Resistance spread in waterways
British and Indian experts are joining forces to investigate the impact that releasing antibiotics from antibiotic manufacturing into India's waterways has on the spread of potentially fatal drug-resistant infections.
British and Indian experts are joining forces to investigate the impact that releasing antibiotics from antibiotic manufacturing into India's waterways has on the spread of potentially fatal drug-resistant infections.
University of Minnesota expands clinical investigation of engineered iPSC-derived natural killer cells, opening U.S. clinical trial for the treatment of COVID-19
The first patient has received treatment in a new clinical trial that has opened at the University of Minnesota to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia (AML) and lymphoma can be effective as a treatment for COVID-19.
The first patient has received treatment in a new clinical trial that has opened at the University of Minnesota to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia (AML) and lymphoma can be effective as a treatment for COVID-19.
Imitation May Be a Sincere Form of Treatment
NIH to launch study of experimental monoclonal antibody therapy for COVID-19; a Q&A with the trial's protocol chair: Davey Smith, MD, at UC San Diego School of Medicine Neutralizing antibodies are th
NIH to launch study of experimental monoclonal antibody therapy for COVID-19; a Q&A with the trial's protocol chair: Davey Smith, MD, at UC San Diego School of Medicine Neutralizing antibodies are th
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
UCL Technology Fund announces first close of £100m Fund 2
UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business (UCLB) (the university's commercialisation company and part of UCL Innovation & Enterprise), announces first close of a £100m target Fund 2.
UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business (UCLB) (the university's commercialisation company and part of UCL Innovation & Enterprise), announces first close of a £100m target Fund 2.
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine
Waisman Biomanufacturing staff operate a centrifuge that allows for cell separation. The UW-Madison biopharmaceutical contract manufacturer is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials.
Waisman Biomanufacturing staff operate a centrifuge that allows for cell separation. The UW-Madison biopharmaceutical contract manufacturer is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials.
Diabetes drug could prevent kidney failure
An affordable diabetes drug could save generations of Australian families who live with polycystic kidney disease from kidney failure.
An affordable diabetes drug could save generations of Australian families who live with polycystic kidney disease from kidney failure.
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
’Rewiring the heart’: UChicago cardiologist provides relief for recurring fainting spells
A procedure conducted for the first time in the United States at the University of Chicago Medicine has provided much-needed relief for a patient who suffered from recurrent fainting spells.
A procedure conducted for the first time in the United States at the University of Chicago Medicine has provided much-needed relief for a patient who suffered from recurrent fainting spells.
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
Covid-19 vaccine trialled in healthy volunteers
A UCL supported trial, which is testing the Covid-19 vaccine candidate developed by Imperial College London, is now recruiting members of the public at UCLH.
A UCL supported trial, which is testing the Covid-19 vaccine candidate developed by Imperial College London, is now recruiting members of the public at UCLH.
UCL supports trialling of Covid-19 vaccine in healthy volunteers
A UCL supported trial, which is testing the Covid-19 vaccine candidate developed by Imperial College London, is now recruiting members of the public at UCLH.
A UCL supported trial, which is testing the Covid-19 vaccine candidate developed by Imperial College London, is now recruiting members of the public at UCLH.
The company is developing treatments that restore gut bacteria in people struggling with a range of diseases.
News in Brief
Health - Jan 11
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Pharmacology - Jan 11
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
History - Jan 10
THURS 28 JAN.: MAKING ART MODERN? VIEWS FROM THE ITALIAN RENAISSANCE- Talk by Robert Brennan with a response by Wolf-Dietrich Löhr
THURS 28 JAN.: MAKING ART MODERN? VIEWS FROM THE ITALIAN RENAISSANCE- Talk by Robert Brennan with a response by Wolf-Dietrich Löhr
Environment - Jan 7
More Root Carbon in Extensive Cultivation Systems - the Greenhouse Gas Inventory Is Optimised
More Root Carbon in Extensive Cultivation Systems - the Greenhouse Gas Inventory Is Optimised
Economics - Jan 7
Keep it simple: Exploring the precarious world of economic forecasting with Prof Michael Gasiorek
Keep it simple: Exploring the precarious world of economic forecasting with Prof Michael Gasiorek